Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

NR4A transcription factors limit CAR T cell function in solid tumours

(2019) Joyce Chen et al.   NATURE

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B cell diffuse large B-cell lymphomas

(2019) Marién Pascual et al.   BLOOD

TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer

(2019) Jitka Fucikova et al.   CLINICAL CANCER RESEARCH

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL

(2019) Maissa Mhibik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report

(2018) Christopher Funk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

(2018) Chulin Sha et al.   JOURNAL OF CLINICAL ONCOLOGY

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

(2017) Annette M. Staiger et al.   JOURNAL OF CLINICAL ONCOLOGY

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma

(2017) Xia Fang et al.   MEDICINE

Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours

(2017) J. Justin Milner et al.   NATURE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma

(2016) Clémence Granier et al.   CANCER RESEARCH

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

(2016) Andrea Schietinger et al.   IMMUNITY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection

(2016) Ran He et al.   NATURE

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications

(2016) Wei Xing et al.   Oncotarget

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

(2016) Ling Dong et al.   Oncotarget

PD-1 expression on the surface of peripheral blood CD4+T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma

(2016) Wei Zhang et al.   Cancer Medicine

Recent advances in paediatric respiratory medicine

(2015) Andrew Turnbull et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma

(2015) Li Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma

(2015) J. Kiyasu et al.   BLOOD

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

(2015) Dohee Kwon et al.   HISTOPATHOLOGY

Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex Ligation-Dependent Probe Amplification Assay

(2015) Sylvain Mareschal et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival

(2015) Z -Z Yang et al.   Blood Cancer Journal

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

(2014) D Rossille et al.   LEUKEMIA

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

(2013) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

"License to Kill" Reflects Joint Action of CD4 and CD8 T Cells

(2013) C. J. M. Melief   CLINICAL CANCER RESEARCH

Persistent Changes in Circulating and Intestinal γδ T Cell Subsets, Invariant Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Children and Adults with Coeliac Disease

(2013) Margaret R. Dunne et al.   PLoS One

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection

(2012) M. A. Paley et al.   SCIENCE

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

(2011) S. T. Wilkinson et al.   BLOOD

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

(2011) Madhavi Challa-Malladi et al.   CANCER CELL

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology